Please assess the completion status of the following clinical trial:

Trial Title: Arterial pH and Total Body Nitrogen Balances in APD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women from any ethnic/racial group \< 65 years.~2. Treatment with CPD for 6 months and current treatment with APD for at least one month.~3. Hemoglobin of at least 11.0 g/dl.~4. Stable dose of erythropoietin treatment for at least the preceding three months.~5. Subjects with normal nutritional status to mild malnutrition:~   1. Serum albumin \> 3.3 g/dl~  2. Relative body weight of 90-120% of the NHANES II median body weight for a given height, age range, gender and frame size.~  3. A normalized protein equivalent of total nitrogen appearance (nPNA) \> 0.80 g/kg actual body weight/day at the time of screening.~6. D/P Cr between 0.48 and 0.81 on the PET performed at the time of the screen.~7. Total (renal + peritoneal) weekly Kt/V urea \> 1.70 and creatinine clearance \> 50 L/wk/1.73 m2.~8. No evidence of primary or secondary (viz., ischemic, neuropathic) myopathy~Exclusion Criteria:~1. History of active cancer other than basal cell carcinoma.~2. Symptomatic severe ischemic heart disease, uncontrolled severe dysrhythmias, uncontrolled congestive heart failure, poorly controlled hypertension, severe musculoskeletal disease, arthritis or amputation of the lower extremities.~3. Insulin requiring diabetes mellitus.~4. Patients who received L-carnitine or anabolic hormones (other than erythropoietin) within the previous 6 months.~5. Use of CaCO3 as phosphate binder.~6. Severe lung or liver disease, uncontrolled asthma, active vasculitis.~7. Severe chronic infection or any other acute or chronic inflammatory or catabolic illnesses (e.g., active tuberculosis, AIDS, osteomyelitis).~8. Psychosis, inability to give informed consent, evidence that patient will not comply with study protocol.~9. Alcohol or other recreational drug abuse.~10. Pregnancy (rare in CPD patients).~11. Patients who are physically and/or psychologically incapable of undergoing the protocol.~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Low normal pH (arterial pH 7.36-7.38) (Type: ACTIVE_COMPARATOR): Ammonium chloride or sodium citrate/citrate acid as needed to achieve the target pH
- High Normal pH (arterial pH 7.44-7.46) (Type: ACTIVE_COMPARATOR): High Normal pH (7.44-7.46) with use of increasing doses of sodium bicarbonate up until the desired pH is achieved

Based on this trial design, predict the completion outcome and termination type (if applicable).